


Appl. No. 10/775,464
Amdt. Dated September 6, 2005
Reply to Office Action of June 29, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.(Currently Amended) A compound of the formula:



or a pharmaceutically acceptable salt thereof;

in which;

- a. M is NZ or O;
- b. Z is represented by H or C₁-C₄ alkyl;
- c. R¹ is represented by hydrogen, (C₁-C₂)alkyl, optionally substituted with one or more halogens, or (C₁-C₂)alkoxy, optionally substituted with one or more halogens;
- d. R² is absent, or may represent up to 2 substituents selected from the group consisting of halogen, nitrile, hydroxy, (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₂-C₄)alkynyl, (C₁-C₄)alkoxy, (C₁-C₂)alkyl substituted with one or more halogens, (C₁-C₂)alkoxy substituted with one or more halogens, SR⁴, and NR⁴R⁵;
- e. X is represented by O or S;

Appl. No. 10/775,464
Amtd. Dated September 6, 2005
Reply to Office Action of June 29, 2005

- f. A is represented by hydrogen, (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, -[CH₂]_mC(O)OR⁴, -[CH₂]_mC(O)R⁴, -[CH₂]_mC(O)NR⁴R⁵, -[CH₂]_m-D-[CH₂]_n-CH₃, or (CH₂)_n-R³-R⁶;
- g. D is O or S;
- h. m is an integer selected from 1 to 6;
- i. n is an integer from 0 to 6;
- j. R³ is represented by optionally substituted phenyl, optionally substituted naphthyl, C₃-C₈ cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclic;
- k. R⁴ and R⁵ are each independently represented by hydrogen, (C₁-C₄)alkyl, optionally substituted benzyl or optionally substituted phenyl, and;
- l. R⁶ is absent, or is represented by a substituent selected from the group consisting of optionally substituted phenyl, optionally substituted naphthyl, optionally substituted phenoxy, C₃-C₈cycloalkyl, optionally substituted heterocyclic, and optionally substituted heteroaryl.

Claim 2 (Cancelled).

Claim 3 (Original) The compound according to claim 2 in which Z is H.

Claim 4 (Cancelled).

Claim 5 (Original) The compound according to claim 1 in which R¹ is -CF₃.

Claim 6 (Original) The compound according to claim 1 in which R² is absent.

Claim 7 (Original) The compound according to claim 1 in which X is O.

Claim 8 (Original) The compound according to claim 1 in which X is S.

Claims 9-11 (Cancelled).

Claim 13 (Original) A pharmaceutical composition comprising a compound according to Claim 1 in admixture with 1, or more, pharmaceutically acceptable excipients.

Appl. No. 10/775,464
Amtd. Dated September 6, 2005
Reply to Office Action of June 29, 2005

Claim 14 (Original) A topical pharmaceutical formulation comprising a compound according to Claim 1 in admixture with 1, or more, pharmaceutically acceptable excipients suitable for dermal application.

Claim 15 (Currently Amended). An kit article of manufacture comprising a compound according to Claim 1 packaged for retail distribution which advises a consumer how to utilize the compound to alleviate a condition selected from the group consisting of acne, alopecia, and oily skin.


Claim 16 (New) A compound according to claim 1 selected from the group consisting of;

1-(1-Methyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-phenylurea;
1-(1-Methyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-phenylthiourea;
1-(1-Methyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-(2-p-tolylethyl)thiourea;
1-[2-(4-Chlorophenyl)ethyl]-3-(1-methyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-phenyl-thiourea;
1-Naphthalen-1-yl-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-Cyclopropylmethyl-3-(2-oxo-4-trifluoromethyl-1,2-dihydro-quinolin-6-yl)thiourea;
1-[2-(3,4-Dimethoxyphenyl)ethyl]-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-(2,4-Dimethoxyphenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-(2,4-Dichlorophenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-Furan-2-ylmethyl-3-(2-oxo-4-trifluoromethyl-1,2-dihydro-quinolin-6-yl)thiourea;
1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-p-tolylthiourea;
1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-(tetrahydrofuran-2-ylmethyl)thiourea;
1-(2-Cyclohex-1-enylethyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-thiourea;
1-(2-Isopropylphenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-(3-trifluoromethylphenyl)thiourea;

Appl. No. 10/775,464
Amtd. Dated September 6, 2005
Reply to Office Action of June 29, 2005

1-(5-Chloro-2,4-dimethoxyphenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-(4-Methoxyphenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-(4-Fluorophenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-(2-Methoxyethyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-thiourea;
1-Allyl-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-(3-Methoxyphenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-(2-p-tolylethyl)thiourea;
1-Methyl-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-[2-(4-Chlorophenyl)ethyl]-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-Isopropyl-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-(4-Cyanophenyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea;
1-(4-Methylbenzyl)-3-(2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)thiourea; and
1-(2-Oxo-4-trifluoromethyl-1,2-dihydroquinolin-6-yl)-3-o-tolylthiourea

Claim 17 (New) A compound of the formula:



or a pharmaceutically acceptable salt thereof;

in which;

- a. M is O;
- b. R¹ is represented by -CF³
- c. R² is absent, or may represent up to 2 substituents selected from the group consisting of halogen, nitrile, hydroxy, (C₁-C₄)alkyl, (C₂-C₄)alkenyl, (C₂-C₄)alkynyl, (C₁-C₄)alkoxy, (C₁-C₂)alkyl substituted with one or more

Appl. No. 10/775,464
Amtd. Dated September 6, 2005
Reply to Office Action of June 29, 2005

halogens, (C₁-C₂)alkoxy substituted with one or more halogens, SR⁴, and NR⁴R⁵;

- d. X is represented by O or S;
- e. A is represented by hydrogen, (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, -[CH₂]_mC(O)OR⁴, -[CH₂]_mC(O)R⁴, -[CH₂]_mC(O)NR⁴R⁵, -[CH₂]_m-D-[CH₂]_n-CH₃, or (CH₂)_n-R³-R⁶;
- f. D is O or S;
- g. m is an integer selected from 1 to 6;
- h. n is an integer from 0 to 6;
- i. R³ is represented by optionally substituted phenyl, optionally substituted naphthyl, C₃-C₈ cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclic;
- j. R⁴ and R⁵ are each independently represented by hydrogen, (C₁-C₄)alkyl, optionally substituted benzyl or optionally substituted phenyl, and;
- k. R⁶ is absent, or is represented by a substituent selected from the group consisting of optionally substituted phenyl, optionally substituted naphthyl, optionally substituted phenoxy, C₃-C₈cycloalkyl, optionally substituted heterocyclic, and optionally substituted heteroaryl.

Claim 18 (New) A topical pharmaceutical formulation comprising a compound according to Claim 17 in admixture with 1, or more, pharmaceutically acceptable excipients suitable for dermal application.

Claim 19 (new) A compound according to claim 16 selected from the group consisting of:
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-phenylthiourea;
1-Naphthalen-1-yl-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;
1-[2-(3,4-Dimethoxyphenyl)ethyl]-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-(4-trifluoromethoxyphenyl)urea;
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-(4-phenoxyphenyl)urea;

Appl. No. 10/775,464
Amdt. Dated September 6, 2005
Reply to Office Action of June 29, 2005

1-Furan-2-ylmethyl-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;
1-(4-Methoxybenzyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)-thiourea;
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-p-tolylthiourea;
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-(tetrahydrofuran-2-ylmethyl)thiourea;
1-(3-Isopropylphenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;
1-Benzo[1,3]dioxol-5-ylmethyl-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-(4-trifluoromethylphenyl)thiourea;
1-(4-Methoxyphenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;
1-(2-Cyclohex-1-enylethyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;
1-(4-Fluorophenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;
1-(3,5-Dichlorophenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)urea;
1-(4-Ethoxyphenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)urea;
1-(3-Methoxyphenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-(2-p-tolylethyl)thiourea;
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-phenethylthiourea;
1-[2-(4-Chlorophenyl)ethyl]-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;
1-(4-Methoxy-2-methylphenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea;
1-(4-Chlorophenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)urea;
1-Hexyl-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)urea;
1-(2-Oxo-4-trifluoromethyl-2H-chromen-6-yl)-3-o-tolylthiourea;
1-(4-Chlorophenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea; and
1-(2,4-Dimethoxyphenyl)-3-(2-oxo-4-trifluoromethyl-2H-chromen-6-yl)thiourea.